BioCentury
ARTICLE | Deals

Third strike for Jyseleca takes therapy out of play in U.S. as focus of Gilead, Galapagos deal shifts to IPF

December 16, 2020 3:07 AM UTC

Four months after Jyseleca’s surprise setback at FDA, Gilead and Galapagos are abandoning U.S. development of the therapy that was once the centerpiece of a $5 billion deal between the companies.  

Investors who spoke with BioCentury after the August complete response letter for Jyseleca filgotinib from  Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) and Gilead Sciences Inc. (NASDAQ:GILD) in rheumatoid arthritis questioned whether the JAK inhibitor still had a chance to compete on the market in RA, ulcerative colitis and other autoimmune indications. ...